Oncoheroes Biosciences Inc. and Boehringer Ingelheim International GmbH Sign Exclusive Licensing Agreement for Volasertib
Summary
Meanwhile, independent academic groups had generated strong data in support of further developing the drug for rhabdomyosarcoma and a few other pediatric cancer indications. By signing this licensing agreement, Oncoheroes and Boehringer Ingelheim make it possible to continue the clinical development of volasertib to the benefit of younger cancer patients. The company was co-founded by Ricardo Garcia and Cesare Spadoni, two parents touched by childhood cancer and determined to change the outlook for these young patients. Under the terms of this agreement Boehringer Ingelheim assigns to Oncoheroes the intellectual property of volasertib, with exclusive rights to research, develop, sell and sublicense the compound. Meanwhile, independent academic groups had generated strong data in support of further developing the drug for rhabdomyosarcoma and a few other pediatric cancer indications.